Related Experiment Video
Updated: Jul 12, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline
S Verma1, J Younus, D Stys-Norman
1Division of Medical Oncology, Ottawa Hospital, Ottawa, Ontario.
Current Oncology (Toronto, Ont.)
|August 22, 2007
Summary
For advanced soft-tissue sarcoma, ifosfamide combination chemotherapy is not recommended as first-line treatment over doxorubicin alone. However, it may be reasonable for symptomatic, locally advanced cases to improve symptoms or resectability.
Area of Science:
- Medical Oncology
- Clinical Practice Guidelines
- Systematic Reviews
Background:
- Prognosis for inoperable or metastatic soft-tissue sarcoma (STS) remains poor.
- Chemotherapy is primarily used for palliative care in most STS patients.
- Ifosfamide shows activity in pre-treated or doxorubicin-resistant STS.
Purpose of the Study:
- To evaluate if ifosfamide-containing combination chemotherapy offers advantages over regimens without ifosfamide for first-line treatment of advanced STS.
- To compare adverse effects and quality of life between ifosfamide-containing and non-ifosfamide regimens.
- To provide evidence-based recommendations for ifosfamide use in STS.
Main Methods:
- Systematic review and meta-analysis of existing studies.
- Evidence synthesis and input from clinical practitioners.
- Review and approval by the Sarcoma Disease Site Group and Report Approval Panel.
Main Results:
- Addition of ifosfamide to standard first-line doxorubicin regimens is not recommended over single-agent doxorubicin for metastatic STS.
- Ifosfamide combined with doxorubicin is a reasonable option for symptomatic, locally advanced STS.
- Recommended ifosfamide dose in combination regimens should not exceed 7.5 g/m(2).
Conclusions:
- First-line ifosfamide combination chemotherapy is not superior to doxorubicin alone for metastatic STS.
- Ifosfamide plus doxorubicin can be considered for locally advanced STS to manage symptoms or facilitate resection.
- Careful dose management of ifosfamide is crucial when used in combination therapy.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...